Dose-escalated Adaptive Radiotherapy for Bladder Cancer: Results of the Phase 2 RAIDER Randomised Controlled Trial

被引：2

作者：

Huddart, Robert ^{[1
,2
]}

Hafeez, Shaista ^{[1
,2
]}

Griffin, Clare ^{[1
]}

Choudhury, Ananya ^{[3
]}

Foroudi, Farshad ^{[4
]}

Syndikus, Isabel ^{[5
]}

Hindson, Benjamin ^{[6
]}

Webster, Amanda ^{[7
,8
]}

Mcnair, Helen ^{[1
,2
]}

Birtle, Alison ^{[9
,10
,11
]}

Varughese, Mohini ^{[12
]}

Henry, Ann ^{[13
,14
]}

Mclaren, Duncan ^{[15
]}

Parikh, Omi ^{[9
]}

Nikapota, Ashok ^{[16
]}

Tang, Colin ^{[17
]}

Patel, Emma ^{[18
]}

Miles, Elizabeth ^{[18
]}

Warren-Oseni, Karole ^{[1
,2
]}

Kron, Tomas ^{[19
]}

Hill, Courtney ^{[20
]}

Philipps, Lara ^{[1
]}

Vassallo-Bonner, Catalina ^{[1
]}

Cheung, Ka Ching ^{[1
]}

Gribble, Hannah ^{[1
]}

Lewis, Rebecca ^{[1
]}

Hall, Emma ^{[1
]}

机构：

[1] Inst Canc Res, Sutton, England

[2] Royal Marsden NHS Fdn Trust, Sutton, England

[3] Christie NHS Fdn Trust, Manchester, England

[4] Austin Hlth, Heidelberg, Vic, Australia

[5] Clatterbridge Canc Ctr, Bebington, England

[6] Christchurch Hosp, Canterbury Reg Canc & Haematol Serv, Christchurch, New Zealand

[7] Univ Coll Hosp, London, England

[8] Univ Coll Hosp, Univ Coll Hosp NHS Fdn Trust, London, England

[9] Lancashire Teaching Hosp NHS Fdn Trust, Royal Preston Hosp, Rosemere Canc Ctr, Preston PR2 9HT, Lancs, England

[10] Univ Manchester, Manchester, England

[11] Univ Cent Lancashire, Preston, England

[12] Royal Devon & Exeter NHS Fdn Trust, Royal Devon & Exeter Hosp, Exeter, England

[13] Univ Leeds, Leeds, England

[14] St James Univ Hosp, Leeds Teaching Hosp NHS Trust, Leeds, England

[15] Western Gen Hosp, NHS Lothian, Edinburgh, Scotland

[16] Royal Sussex Cty Hosp, Brighton & Sussex Univ Hosp NHS Trust, Brighton, England

[17] Sir Charles Gairdner Hosp, Nedlands, WA, Australia

[18] Mt Vernon Hosp, Natl Radiotherapy Trials Qual Assurance Grp RTTQA, Northwood, England

[19] Peter Maallum Canc Ctr, Melbourne, Vic, Australia

[20] TROG Canc Res, Waratah, NSW, Australia

来源：

EUROPEAN UROLOGY | 2025年 / 87卷 / 01期

关键词：

Adaptive radiotherapy; Image-guided radiotherapy; Radiotherapy; Randomised controlled trial; LONG-TERM OUTCOMES; GASTROINTESTINAL SYMPTOMS; RADIATION-THERAPY; QUESTIONNAIRE; VOLUME;

D O I：

10.1016/j.eururo.2024.09.006

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Background and objective: Delivering radiotherapy to the bladder is challenging as it is a mobile, deformable structure. Dose-escalated adaptive image-guided radiotherapy could improve outcomes. RAIDER aimed to demonstrate the safety of such a schedule. Methods: RAIDER is an international phase 2 noncomparative randomised controlled trial (ISRCTN26779187). Patients with unifocal T2-T4a urothelial bladder cancer were randomised (1:1:2) to standard whole bladder radiotherapy (WBRT), standard-dose adaptive radiotherapy (SART), or dose-escalated adaptive radiotherapy (DART). Two fractionation (f) schedules recruited independently. WBRT and SART dose was 55 Gy/20f or 64 Gy/32f, and DART dose was 60 Gy/20f or 70 Gy/32f. For SART and DART, a radiotherapy plan (small, medium, or large) was chosen daily. The primary endpoint was the proportion of patients with radiotherapy-related late Common Terminology Criteria for Adverse Events grade >= 3 toxicity; the trial was designed to rule Key findings and limitations: A total of 345 patients were randomised between October 2015 and April 2020: 41/46 WBRT, 41/46 SART, and 81/90 DART patients in the 20f/32f

引用

页码：60 / 70

页数：11

共 29 条

[1] Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) [J].

Basch, Ethan ;

Reeve, Bryce B. ;

Mitchell, Sandra A. ;

Clauser, Steven B. ;

Minasian, Lori M. ;

Dueck, Amylou C. ;

Mendoza, Tito R. ;

Hay, Jennifer ;

Atkinson, Thomas M. ;

Abernethy, Amy P. ;

Bruner, Deborah W. ;

Cleeland, Charles S. ;

Sloan, Jeff A. ;

Chilukuri, Ram ;

Baumgartner, Paul ;

Denicoff, Andrea ;

St Germain, Diane ;

O'Mara, Ann M. ;

Chen, Alice ;

Kelaghan, Joseph ;

Bennett, Antonia V. ;

Sit, Laura ;

Rogak, Lauren ;

Barz, Allison ;

Paul, Diane B. ;

Schrag, Deborah .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (09)

[2] Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: A pooled individual data analysis of eight phase I-II trials [J].

Caffo, Orazio ;

Thompson, Catherine ;

De Santis, Maria ;

Kragelj, Borut ;

Hamstra, Daniel A. ;

Azria, David ;

Fellin, Gianni ;

Pappagallo, Giovanni L. ;

Galligioni, Enzo ;

Choudhury, Ananya .

RADIOTHERAPY AND ONCOLOGY, 2016, 121 (02) :193-198

[3] Radiotherapy for muscle-invasive carcinoma of the bladder: Results of a randomized trial comparing conventional whole bladder with dose-escalated partial bladder radiotherapy [J].

Cowan, RA ;

McBain, CA ;

Ryder, WDJ ;

Wylie, JP ;

Logue, JP ;

Turner, SL ;

Van Der Voet, J ;

Collins, CD ;

Khoo, VS ;

Read, GR .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (01) :197-207

[4] Inter- and intra-fractional bladder motion during radiotherapy for bladder cancer: A comparison of full and empty bladders [J].

Dees-Ribbers, Hermine M. ;

Betgen, Anja ;

Pos, Floris J. ;

Witteveen, Thelma ;

Remeijer, Peter ;

van Herk, Marcel .

RADIOTHERAPY AND ONCOLOGY, 2014, 113 (02) :254-259

[5] Late Pelvic Toxicity After Bladder-Sparing Therapy in Patients With Invasive Bladder Cancer: RTOG 89-03, 95-06, 97-06, 99-06 [J].

Efstathiou, Jason A. ;

Bae, Kyounghwa ;

Shipley, William U. ;

Kaufman, Donald S. ;

Hagan, Michael P. ;

Heney, Niall M. ;

Sandler, Howard M. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (25) :4055-4061

[6] Comparison of Margins, Integral Dose and Interfraction Target Coverage with Image-guided Radiotherapy Compared with Non-image-guided Radiotherapy for Bladder Cancer [J].

Foroudi, F. ;

Pham, D. ;

Bressel, M. ;

Hardcastle, N. ;

Gill, S. ;

Kron, T. .

CLINICAL ONCOLOGY, 2014, 26 (08) :497-505

[7] Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience [J].

Giacalone, Nicholas J. ;

Shipley, William U. ;

Clayman, Rebecca H. ;

Niemierko, Andrzej ;

Drumm, Michael ;

Heney, Niall M. ;

Michaelson, Marc D. ;

Lee, Richard J. ;

Saylor, Philip J. ;

Wszolek, Matthew F. ;

Feldman, Adam S. ;

Dahl, Douglas M. ;

Zietman, Anthony L. ;

Efstathiou, Jason A. .

EUROPEAN UROLOGY, 2017, 71 (06) :952-960

[8] Failing to Close the Gap Between Evidence and Clinical Practice in Radical Bladder Cancer Radiotherapy [J].

Hafeez, S. ;

Lewis, R. ;

Griffin, C. ;

Hall, E. ;

Huddart, R. .

CLINICAL ONCOLOGY, 2021, 33 (01) :46-49

[9]

Hafeez S, 2020, INT J RADIAT ONCOL, V108, pS29

[10] Protocol for tumour-focused dose-escalated adaptive radiotherapy for the radical treatment of bladder cancer in a multicentre phase II randomised controlled trial (RAIDER): radiotherapy planning and delivery guidance [J].

Hafeez, Shaista ;

Webster, Amanda ;

Hansen, Vibeke N. ;

McNair, Helen A. ;

Warren-Oseni, Karole ;

Patel, Emma ;

Choudhury, Ananya ;

Creswell, Joanne ;

Foroudi, Farshad ;

Henry, Ann ;

Kron, Tomas ;

McLaren, Duncan B. ;

Mitra, Anita, V ;

Mostafid, Hugh ;

Saunders, Daniel ;

Miles, Elizabeth ;

Griffin, Clare ;

Lewis, Rebecca ;

Hall, Emma ;

Huddart, Robert .

BMJ OPEN, 2020, 10 (12)

← 1 2 3 →